Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;71(1):47-77.
doi: 10.3322/caac.21636. Epub 2020 Aug 27.

Onconephrology: The intersections between the kidney and cancer

Mitchell H Rosner  1 , Kenar D Jhaveri  2 , Blaithin A McMahon  3 , Mark A Perazella  4
Affiliations
Free article
Review

Onconephrology: The intersections between the kidney and cancer

Mitchell H Rosner et al. CA Cancer J Clin. 2021 Jan.
Free article

Abstract

Onconephrology is a new subspecialty of nephrology that recognizes the important intersections of kidney disease with cancer. This intersection takes many forms and includes drug-induced nephrotoxicity, electrolyte disorders, paraneoplastic glomerulonephritis, and the interactions of chronic kidney disease with cancer. Data clearly demonstrate that, when patients with cancer develop acute or chronic kidney disease, outcomes are inferior, and the promise of curative therapeutic regimens is lessened. This highlights the imperative for collaborative care between oncologists and nephrologists in recognizing and treating kidney disease in patients with cancer. In response to this need, specific training programs in onconephrology as well as dedicated onconephrology clinics have appeared. This comprehensive review covers many of the critical topics in onconephrology, with a focus on acute kidney injury, chronic kidney disease, drug-induced nephrotoxicity, kidney disease in stem cell transplantation, and electrolyte disorders in patients with cancer.

Keywords: acute kidney injury; chemotherapy; chronic kidney disease; electrolytes; glomerulonephritis; immunotherapy; kidney; myeloma; stem cell; transplantation.

PubMed Disclaimer

References

    1. Launay-Vacher V, Oudard S, Janus N, et al; Renal Insufficiency and Cancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer. 2007;110:1376-1384.
    1. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA Study Group. Semin Nephrol. 2010;30:548-556.
    1. Iff S, Craig JC, Turner R, et al. Reduced estimated GFR and cancer mortality. Am J Kidney Dis. 2014;63:23-30.
    1. Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open. 2016;1:e000091.
    1. Janus N, Launay-Vacher V, Byloos E, et al. Cancer and renal insufficiency: results of the BIRMA study. Br J Cancer. 2010;103:1815-1821.

MeSH terms

Substances

LinkOut - more resources